cytarabine

Type: Keyphrase
Name: cytarabine
First reported 13 hours ago - Updated 13 hours ago - 1 reports

Celator(R) Pharmaceuticals to Report Second Quarter 2014 Financial Results on August 7, 2014

(GLOBE NEWSWIRE) -- ., (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that it will host a conference call and live audio webcast on Thursday, August 7, 2014 at 4:30 p.m. ET to report ... [Published Pettinga Financial Advisors - 13 hours ago]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Synta Updates on Advancement of Ganetespib into Phase 3 Extension of AML LI-1 Trial [Professional Services Close - Up]

Synta Pharmaceuticals Corp. reported the advancement of ganetespib into the Phase 3 extension of the AML LI-1 trial.AML LI-1 is a multicenter, randomized Phase 2/3 clinical study evaluating several novel treatment regimens, including the combination of ... [Published Pharmacy Choice - Jul 30 2014]
First reported Jul 28 2014 - Updated Jul 28 2014 - 1 reports

Findings from University Medical Center Provide New Insights into Pre-Trial Research (Volasertib for the treatment of acute myeloid leukemia: a...

Findings from University Medical Center Provide New Insights into Pre-Trial Research (Volasertib for the treatment of acute myeloid leukemia: a review of preclinical and clinical development)By a News Reporter-Staff News Editor at Clinical Trials Week ... [Published Pharmacy Choice - Jul 28 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Synta announces Phase III extension of acute myeloid leukemia study

Synta Pharmaceuticals Corp., a biopharmaceutical company, has announced the advancement of ganetespib into the Phase III extension of the AML LI-1 trial for acute myeloid leukemia, or AML, and high-risk myelodysplastic syndrome, or MDS. AML LI-1 is a ... [Published Individual.com - Jul 25 2014]
First reported Jul 23 2014 - Updated Jul 23 2014 - 1 reports

Celator: A Unique Drug Ratio Technology Company For Cancer

By Tony Schwartz, PhD :Company OverviewRelated Biotechnology, Pharmaceutical and Healthcare NewsCelator Pharmaceuticals (NASDAQ: CPXX ) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various ... [Published BioPortfolio - Jul 23 2014]
First reported Jul 22 2014 - Updated Jul 22 2014 - 1 reports

Tumour not end of war

Keely Johnson at Open Mic Night at the Burdekin Theatre Source: SuppliedFOR Keely Johnson, even catching a cold could be fatal.But the brave Burdekin teen has refused to let her battle against an undiagnosed brain tumour hold her back from fighting for ... [Published Townsville Bulletin - Jul 22 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

CPXX: Update on CPX-351 and Technology Platform at Analyst Day

By Grant Zeng, CFANASDAQ:CPXXOn July 17, 2014, Celator Pharmaceuticals ( CPXX ) updates on its lead candidate CPX-351 and CombiPlex (R)  technology platform at its Analyst Day meeting for analysts and investors in NYC.CPX-351 to be Explored in Additional ... [Published Yahoo! Finance - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 18 2014 - 2 reports

Celator Broadens Application of CombiPlex Platform and CPX-351 for AML Treatment

Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today will present updates on its lead candidate CPX-351 and CombiPlex ® technology platform at its Analyst Day meeting for analysts and ... [Published Azonano - Jul 18 2014]
First reported Jul 09 2014 - Updated Jul 10 2014 - 3 reports

Volasertib Phase II data published including new overall survival results in older patients with acute myeloid leukemia

Ratings require JavaScript to be enabled.Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy , versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today ... [Published Medical News Today - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 1 reports

Boehringer Ingelheim's volasertib Phase II data including new overall survival results in older patients with acute myeloid leukemia published in Blood

RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published ... [Published PR Newswire: Health - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Boehringer's breakthrough leukaemia drug hits Ph II targets

An experimental therapy for a subtype of leukaemia awarded 'breakthrough' status on both sides of the Atlantic has continued to impress by hitting targets in a Phase II clinical trial.Boehringer Ingelheim's polo-like kinase inhibitor Volasertib was shown ... [Published Pharma Times - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

AML Regimen Produced Mixed Results in Older Patients

the Chemotherapy Advisor take:Older patients with acute myeloid leukemia (AML) generally have a poor prognosis. Depending on factors such as comorbidities, performance status, and biologic risk characteristics of the disease, older patients’ median overall ... [Published Chemotherapy Advisor - Jul 08 2014]

Quotes

...Vojo Vukovic, Chief Medical Officer, Synta. "We look forward to elucidating this potential through large, randomized studies, including the ongoing Company-sponsored GALAXY-2 PhasePhase 3 trial in advanced non-small cell lung adenocarcinoma and investigator- sponsored trials in AML/MDS, breast cancer and ovarian cancer."
According to the news editors, the research concluded: "Volasertib has not yet been approved for regular clinical use."
"Ultimately," they say, "the question of whether gemtuzumab ozogamicin provides overall benefit with acceptable early mortality remains unanswered, and the optimum dose and dosing schedule are unknown."
Lawrence Mayer, Founder, President and CSO of Celator Pharmaceuticals stated, "The drug ratio principles of our CombiPlex technology apply to combinations of targeted drugs, particularly those that require simultaneous exposure for optimal efficacy. We believe that sustained exposure of tumor cells to optimal ratios of molecularly targeted combinations via CombiPlex will positively impact patient outcomes." Preclinical data from these new molecular targeting studies are expected in the third quarter of 2015

More Content

All (65) | News (56) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Celator(R) Pharmaceuticals to Report Second Qua... [Published Pettinga Financial Advisors - 13 hours ago]
Synta Updates on Advancement of Ganetespib into... [Published Pharmacy Choice - Jul 30 2014]
Baylor Sammons Cancer Center Joins as Clinical ... [Published Wall Street Select - Jul 30 2014]
Findings from University Medical Center Provide... [Published Pharmacy Choice - Jul 28 2014]
Synta announces Phase III extension of acute my... [Published Individual.com - Jul 25 2014]
Mylotarg Boosts Survival in Acute Myeloid Leukemia [Published American Journal of Public Health - Jul 24 2014]
Celator: A Unique Drug Ratio Technology Company... [Published BioPortfolio - Jul 23 2014]
Celator: A Unique Drug Ratio Technology Company... [Published Seeking Alpha - Jul 23 2014]
Tumour not end of war [Published Townsville Bulletin - Jul 22 2014]
Non-Hodgkins Lymphoma Therapeutics Market - Glo... [Published MyNewsDesk - Jul 22 2014]
Synta Announces Ganetespib Into Phase 3 Extensi... [Published BioMedReports - Jul 22 2014]
CPXX: Update on CPX-351 and Technology Platform... [Published Yahoo! Finance - Jul 21 2014]
Celator Pharmaceuticals Stock Rating Reaffirmed... [Published American Banking News - Jul 21 2014]
Boehringer Ingelheim's volasertib Phase II data... [Published Pharmacy Choice - Jul 21 2014]
Celator Broadens Application of CombiPlex Platf... [Published Azonano - Jul 18 2014]
Primary CNS Lymphoma: The Role of Resection [Published Cancernetwork.com - Jul 18 2014]
MicroRNA-140-5p as a tumor suppressor and sensi... [Published PharmCast - Jul 18 2014]
Surgery for Primary Central Nervous System Lymp... [Published Cancernetwork.com - Jul 18 2014]
Celator(R) Pharmaceuticals Provides Update on C... [Published Virtual Strategy Magazine - Jul 17 2014]
Sunesis' Pediatric Plan Accepted in the EU [Published Zacks.com - Jul 14 2014]
Older Acute Myeloid Leukemia Patients May Benef... [Published Chemotherapy Advisor - Jul 11 2014]
Trillium Therapeutics: An Preclinical Cancer Im... [Published Seeking Alpha - Jul 11 2014]
Volasertib Phase II data published including ne... [Published Medical News Today - Jul 10 2014]
Novel Agent Volasertib Doubles Responses in AML [Published Diabetes Care - Jul 09 2014]
BI Posts Positive Results for Leukemia Drug [Published Drug Discovery and Development - Jul 09 2014]
Sunesis Pharmaceuticals Announces European Medi... [Published Benzinga.com - Jul 09 2014]
Boehringer blood cancer drug scores in Phase II [Published Pharmafocus - Jul 09 2014]
Boehringer's breakthrough leukaemia drug hits P... [Published Pharma Times - Jul 08 2014]
AML Regimen Produced Mixed Results in Older Pat... [Published Chemotherapy Advisor - Jul 08 2014]
Boehringer Ingelheim’s volasertib showed in a P... [Published EON: Enhanced Online News - Jul 08 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Boehringer Ingelheim's volasertib Phase II data... [Published PR Newswire: Health - Jul 08 2014]
RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published ...
CYTARABINE Injection, Powder, Lyophilized, For ... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 12, 2014 EST ...
CYTARABINE Injection, Powder, Lyophilized, For ... [Published DailyMed Drug Label Updates for the last seven ... - Jun 12 2014]
Updated Date: Jun 12, 2014 EST ...
CTI Announces United Kingdom National Cancer Re... [Published PR Newswire: Health - Jun 12 2014]
SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients ...
CYTARABINE Injection, Powder, Lyophilized, For ... [Published DailyMed Drug Label Updates for the last seven ... - Jun 02 2014]
Updated Date: May 30, 2014 EST ...
1 2

Press Releases

sort by: Date | Relevance
Celator(R) Pharmaceuticals Announces Data and S... [Published GlobeNewswire: Acquisitions News - Jun 11 2014]
Celator(R) Pharmaceuticals Reaches 75% Enrollme... [Published GlobeNewswire: Acquisitions News - Jun 04 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.